Navigation Links
Diabetes slows nerve recovery after heart transplant

Diabetes has a detrimental effect on a person's ability to recover from a heart transplant, notes a study in the September Journal of Nuclear Medicine.

"Using positron emission tomography (PET) and the transplanted heart as a very specific model to study the regenerative capacity of the heart's sympathetic nervous system, we determined that reinnervation--or the heart's ability to develop new nerves to replace damaged ones--is slower in diabetic patients," said Frank M. Bengel, a visiting associate professor of radiology and the director of cardiovascular nuclear medicine at Johns Hopkins Medicine's Russell H. Morgan Department of Radiology and Radiological Science in Baltimore, Md. "Our results confirm a detrimental effect of diabetes on the potential for recovery of sympathetic nerve fibers of the heart," added the co-author of "Effect of Diabetes Mellitus on Sympathetic Neuronal Regeneration Studied in the Model of Transplant Reinnervation."

"A better understanding of the importance of nervous system abnormalities and an imaging technique to precisely characterize nerve damage may be of value to guide future therapeutic efforts aimed at reducing cardiac risk with diabetes mellitus patients," explained Bengel, who was an associate professor at the Technical University of Munich, where the study was performed, prior to his move to Johns Hopkins. "Even if a transplant recipient is suffering from diabetes, there is still a chance for reinnervation--just at a slower speed," he added. "Unfortunately, there are no techniques developed yet that speed the nerve regeneration process," he said.

Currently, nuclear medicine techniques (such as PET) are the only imaging techniques that can measure the presence and function of the sympathetic nervous system of the heart, said Bengel. "There are invasive methods that allow for the measurement of neurotransmitters released to the blood, offering indirect conclusions about the presence, storage and releas e of neurotransmitters from neurons. These methods require complicated and laborious sampling of blood from coronary arteries and veins," he added.

Diabetes mellitus is a chronic disease that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Such a deficiency results in increased concentrations of glucose (sugar) in the blood, which can damage many of the body's systems. Diabetes mellitus is a known major risk factor of heart disease, negatively affecting the heart's contraction and rhythm, said Bengel.

Future research will need to focus on how regeneration of sympathetic nerves can be facilitated and how changes of the sympathetic nerve integrity in the heart are interrelated with changes of prognosis and outcome of diseases like diabetes mellitus, said Bengel.

"Effect of Diabetes Mellitus on Sympathetic Neuronal Regeneration Studied in the Model of Transplant Reinnervation" appears in the September issue of the Journal of Nuclear Medicine, which is published by SNM. Other co-authors include Peter Ueberfuhr and Bruno Reichart, Ludwig-Maximilians University in Munich, Germany; and Dominik Schäfer, Stephan G. Nekolla and Markus Schwaiger, all with the Technical University of Munich, Germany.
'"/>

Source:Society of Nuclear Medicine


Related biology news :

1. FDA Approves New Drug to Treat Type I and Type II Diabetes
2. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes
3. Single-donor Islet Transplantation Procedure Shows Promise For Patients With Type 1 Diabetes
4. Precise Timing Enabled Pig-to-rat Transplants To Cure Diabetes
5. Diabetes researchers pioneer islet cell xenotransplantation in primate studies
6. Diabetes hits 275 Australians each day as pandemic spreads
7. Diabetes research takes wing thanks to long-lived fruit fly
8. Cancer drug slows poxvirus in mice
9. Stress substantially slows human bodys ability to heal
10. Cell therapy slows progression of an inherited neurological disease; Improves motor skills in mice
11. Protein found that slows hepatitis C growth in liver cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology: